ArticlemedRxiv : the preprint server for health sciences2026
CSF proteome-wide study of neuropsychiatric symptoms of dementia.
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Introduction: Neuropsychiatric symptoms in dementia (NPS) are common and among the most troubling aspects of living with dementia, yet their underlying mechanisms remain unclear. Here, we aimed to identify cerebrospinal fluid (CSF) proteins associated with NPS. Methods: Proteomes were profiled from CSF collected at baseline from participants of the Alzheimer's Disease Neuroimaging Initiative (ADNI) using mass spectrometry. Here, we included participants having positive AD CSF biomarkers (i.e., pTtau181 / Aβ42 ratio >0.025) and mild cognitive impairment or AD dementia (n=419). Eight NPS domains were assessed longitudinally with the Neuropsychiatric Symptom Inventory Questionnaire. Severity of cognitive impairment was evaluated using the CDR-SB. Proteome-wide differential expression analysis for each NPS domain at baseline was performed. Significant protein-NPS associations underwent mediation analysis to test whether they were mediated by cognitive impairment severity. Cox proportional hazard was modeled for baseline CSF proteins and incident NPS. Additionally, we tested whether candidate NPS causal proteins previously identified in brain are associated with NPS in CSF. Results: We identified 8 CSF proteins associated with apathy at baseline (FDR q<0.05) after adjusting for sex, age, and education - NTNG2, S100A1, FZD1, FSTL5, CDH7, CHODL, FBXO2, and CACNA2D2. Mediation analysis revealed these associations were independent of cognitive impairment severity in four proteins and only partially mediated by cognitive impairment severity in the remaining four proteins. Among the 10 NPS candidate causal proteins previously identified in brain and detected in CSF, the abundance of two proteins (CPD, GRN) in CSF was associated with baseline disinhibition and of two other proteins (PIK3IP1, PCMT1) with both baseline apathy and incident apathy after adjusting for sex, age, and education. Discussion: These findings suggest that proteomic alterations in apathy in MCI/AD encompass synaptic connectivity, calcium regulation, Wnt-signaling, and neuronal proteostasis, highlighting potential CSF biological processes and biomarker candidates for apathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.